astrazeneca
AstraZeneca agreed to pay $3.1 million to settle a New York State Attorney General's lawsuit saying the British pharmaceutical company improperly promoted and marketed the schizophrenia drug Seroquel, concealing dangerous side effects such as diabetes from health care providers and the public.
New...
The 10 Biggest-Selling Drugs That Are About to Lose Their Patent
8:00AM 2/27/2011
Company News, Investing, Health Care, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Merck, Eli Lilly, Astrazeneca
The pharmaceutical industry is ready to fall off a cliff -- a "patent cliff." Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from drugmakers' bottom lines.
Pfizer Joins Other Pharmas in Giving a Cautious Outlook
3:41PM 2/01/2011
Company News, Health Care, Earnings, Pfizer, Bristol-Myers Squibb, Novartis, Eli Lilly, Astrazeneca
Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What's ahead for the world's biggest drugmaker:
AstraZeneca's Brilinta Fails to Win FDA Approval
8:08AM 12/17/2010
Company News, Health Care, Pfizer, Bristol-Myers Squibb, Sanofi Aventis, Astrazeneca, Stocks in the News
The FDA disappointed AstraZeneca and its investors by not approving its heart drug Brilinta, a blood-thinner that the company -- facing a severe patent cliff -- has high hopes for. If approved, it could be a multibillion-dollar blockbuster. But the FDA wants to see more analyses of results from a major study.
FDA Is Set Decide the Fate of AstraZeneca's Heart Drug Brilinta
9:35AM 12/15/2010
Company News, Health Care, Bristol-Myers Squibb, Sanofi Aventis, Eli Lilly, Astrazeneca, Stocks in the News
More than a year after AstraZeneca filed for approval, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome -- but approval isn't a sure thing, due in part to some oddities in the study's results.
AstraZeneca Looking to Sell Unit for $2 Billion
11:00AM 11/16/2010
As the Anglo-Swedish drugmaker looks to divest assets, it seeks a buyer for its dental implants and medical devices unit Astra Tech.
AstraZeneca and Pozen announced Monday that their pain reliever Vimovo for the treatment of arthritis had received positive agreement for approval by the 23 E.U. nations. Vimovo is a combination drug that reduces the risk of ulcers for frequent NSAID users.
It's a busy day at the FDA today as panels meet to discuss two new drugs -- one to help weight loss and the other to combat drug addiction -- and decide whether to approve AstraZeneca's new blood thinner medication.
AstraZeneca Agrees to Settle Seroquel Claims for $198 Million
7:52AM 8/09/2010
AstraZeneca (AZN) announced Monday it had reached agreements to settle approximately 17,500 Seroquel product liability suits in the U.S. for some $198 million. The suits allege that anti-psychotic Seroquel causes weight-gain diabetes in some patients.
The agreements in principle are subject to...
AstraZeneca's core earnings per share rose 9% in the second quarter, helped by a strong performance in emerging markets. While the British pharmaceutical warned the rest of the year will be "challenging," it also raised its 2010 earnings forecast for the third time this year.
More Stories
Next Page →Market Movers
| Symbol | Last | Change / % | Volume |
|---|
Most Actives
| 8.11 | -0.08 -0.92% | 127.06M | |
| 2.20 | +0.26 +13.40% | 82.46M | |
| 29.61 | -2.38 -7.44% | 19.63M | |
| 18.84 | -0.29 -1.52% | 18.58M |
% Gainers
| 30.94 | +7.04 +29.46% | 10.42M | |
| 87.49 | +11.10 +14.53% | 5.78M | |
| 10.70 | +1.30 +13.83% | 2.46M | |
| 2.20 | +0.26 +13.40% | 82.46M |
% Losers
DailyFinance Wire
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
Newswire
- Greece caught between protests, austerity...
- Stocks fall sharply as Greek deal is held up
- Turbo-traders take Bank of America for a ride
- Donald Trump blasts plans for Scottish wind...
- Trade deficit widens to $48.8 billion in...
- Feds investigate door fires in 2007 Camrys,...
- NYSE Euronext profit down on blocked merger...
- Obama call for manufacturing revival a tough...
- Morning Movers (CIE, ALU, LNKD, AMRS, XIDE)
- AEP Dividend Growth Still Looks Safe Ahead (AEP)
- Arch Coal Tumbles on Earnings, Forecast (ACI, ANR, PCX, BTU, CNX)
- 2011 Trade Deficit Hits 3-Year High, Over $550 Billion
- Today’s Best Market Rumors (2/10/2012) Apple iPad, Google Entertainment
- Top Analyst Upgrades & Downgrades (ALTR, AMSC, BIIB, CELG, COH, CSTR, COP, FSLR, GILD, HAIN, MA, RF, TRLG)
- Morning Wire — US Stock-Index Futures Down Sharply
- Alcatel-Lucent Pulls a Rabbit Out of Its Hat on Earnings (ALU)
Follow Us
